Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

St. John's Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John's Trial).

Trana C, Toth G, Wijns W, Barbato E.

J Cardiovasc Transl Res. 2013 Jun;6(3):411-4. doi: 10.1007/s12265-013-9455-2. Epub 2013 Mar 6.

PMID:
23463297
[PubMed - indexed for MEDLINE]
2.

High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.

Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F.

JACC Cardiovasc Interv. 2013 Feb;6(2):169-79. doi: 10.1016/j.jcin.2012.09.013.

PMID:
23428009
[PubMed - indexed for MEDLINE]
Free Article
3.

The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity.

Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA.

J Cardiovasc Pharmacol. 2011 Jan;57(1):86-93. doi: 10.1097/FJC.0b013e3181ffe8d0.

PMID:
20980920
[PubMed - indexed for MEDLINE]
4.
5.

Impact of initial clinical presentation on clopidogrel low response.

Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche JM, Lemesle G.

Arch Cardiovasc Dis. 2013 Nov;106(11):593-600. doi: 10.1016/j.acvd.2013.06.050. Epub 2013 Sep 23.

PMID:
24070598
[PubMed - indexed for MEDLINE]
6.

Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.

Ha SJ, Kim SJ, Hwang SJ, Woo JS, Kim W, Kim WS, Kim KS, Kim MK.

Coron Artery Dis. 2013 Dec;24(8):690-7. doi: 10.1097/MCA.0000000000000026.

PMID:
24152567
[PubMed - indexed for MEDLINE]
7.

Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.

Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS.

Am J Cardiol. 2009 May 15;103(10):1339-43. doi: 10.1016/j.amjcard.2009.01.341. Epub 2009 Apr 1.

PMID:
19427425
[PubMed - indexed for MEDLINE]
8.

Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.

Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD.

Vasc Health Risk Manag. 2013;9:187-93. doi: 10.2147/VHRM.S43909. Epub 2013 May 1.

PMID:
23662064
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

N-3 polyunsaturated fatty acids do not influence the efficacy of dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.

Mizia-Stec K, Mizia M, Haberka M, Lasota B, Gieszczyk-Strózik K, Chmiel A, Najda J, Gąsior Z, Kyrcz-Krzemień S.

Cardiol J. 2013;20(5):478-85. doi: 10.5603/CJ.2013.0132.

PMID:
24469870
[PubMed - indexed for MEDLINE]
Free Article
10.

High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.

Chirumamilla AP, Maehara A, Mintz GS, Mehran R, Kanwal S, Weisz G, Hassanin A, Hakim D, Guo N, Baber U, Pyo R, Moses JW, Fahy M, Kovacic JC, Dangas GD.

JACC Cardiovasc Imaging. 2012 May;5(5):540-9. doi: 10.1016/j.jcmg.2011.12.019.

PMID:
22595163
[PubMed - indexed for MEDLINE]
Free PMC Article
11.
12.

Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.

Muller O, Hamilos M, Bartunek J, Ulrichts H, Mangiacapra F, Holz JB, Ntalianis A, Trana C, Dierickx K, Vercruysse K, De Bruyne B, Wijns W, Barbato E.

Am J Cardiol. 2010 Feb 1;105(3):333-8. doi: 10.1016/j.amjcard.2009.09.033. Epub 2009 Dec 22.

PMID:
20102944
[PubMed - indexed for MEDLINE]
13.

Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel.

Hamilos M, Muller O, Ntalianis A, Trana C, Bartunek J, Sarno G, Mangiacapra F, Dierickx K, Meeus P, Cuisset T, De Bruyne B, Wijns W, Barbato E.

J Thromb Thrombolysis. 2011 Jul;32(1):64-71. doi: 10.1007/s11239-011-0557-x.

PMID:
21290254
[PubMed - indexed for MEDLINE]
14.

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F.

Circ Cardiovasc Interv. 2012 Oct;5(5):698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463. Epub 2012 Oct 9.

PMID:
23048056
[PubMed - indexed for MEDLINE]
Free Article
15.

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.

Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N.

J Am Coll Cardiol. 2009 Mar 10;53(10):849-56. doi: 10.1016/j.jacc.2008.11.030.

PMID:
19264241
[PubMed - indexed for MEDLINE]
Free Article
16.

Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).

Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G.

Am J Cardiol. 2011 Apr 1;107(7):995-1000. doi: 10.1016/j.amjcard.2010.11.025. Epub 2011 Jan 20.

PMID:
21256470
[PubMed - indexed for MEDLINE]
17.

Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome.

de Miguel Castro A, Cuellas Ramón C, Diego Nieto A, Samaniego Lampón B, Alonso Rodríguez D, Fernández Vázquez F, Alonso Orcajo N, Carbonell de Blas R, Pascual Vicente C, Pérez de Prado A.

Rev Esp Cardiol. 2009 Feb;62(2):126-35. English, Spanish.

PMID:
19232185
[PubMed - indexed for MEDLINE]
Free Article
18.

Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention.

Mangiacapra F, Cavallari I, Barbato E, Ricottini E, Patti G, Vizzi V, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G.

Am J Cardiol. 2014 Apr 1;113(7):1124-9. doi: 10.1016/j.amjcard.2013.12.018. Epub 2014 Jan 14.

PMID:
24507863
[PubMed - indexed for MEDLINE]
19.

Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention.

Pendyala LK, Torguson R, Loh JP, Devaney JM, Chen F, Kitabata H, Minha S, Barbash IM, Suddath WO, Satler LF, Pichard AD, Waksman R.

Am Heart J. 2013 Aug;166(2):266-72. doi: 10.1016/j.ahj.2013.04.008. Epub 2013 May 23.

PMID:
23895809
[PubMed - indexed for MEDLINE]
20.

Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.

Ang L, Thani KB, Ilapakurti M, Lee MS, Palakodeti V, Mahmud E.

J Am Coll Cardiol. 2013 Jan 8;61(1):23-34. doi: 10.1016/j.jacc.2012.09.037.

PMID:
23287370
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk